Trastuzumab emtansine versus treatment of physician's choice in patients with previously treated HER2-positive metastatic breast cancer (TH3RESA): final overall survival results from a randomised open-label phase 3 trial

1. Krop, I.E.
2. Kim, S.-B.
3. Martin, A.G.
4. LoRusso, P.M.
5. Ferrero, J.-M.
6. Badovinac-Crnjevic, T.
7. Hoersch, S.
8. Smitt, M.
9. Wildiers, H.